Compare Regeneron Pharmaceuticals Inc (REGN) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vital Farms Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while Vital Farms Inc trades at $9.33 (market cap $405.27M). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 187.9× Vital Farms Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Vital Farms Inc for 14 Days on average.
| REGN | VITL | |
|---|---|---|
Market Cap | $76.14B | $405.27M |
Volume | 500,239 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $852.03 | $43.40 |
52-Week Low | $557.73 | $8.28 |
Typical Hold Time | 107 Days | 14 Days |
Enterprise Value | $70.85B | $492.28M |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Vital Farms (VITL) trades at $9.435, up 2.11% today, amid a challenging period marked by volatile earnings and a bearish technical signal. The stock shows weak profitability with a net income margin of 0.02% in 2026, though valuation ratios like P/S of 0.55 appear attractive. Recent news highlights strategic review for a potential sale, with price targets ranging from $10 to $20. Cash flow remains negative, driven by heavy investing activities, while institutional interest persists with new acquisitions.
The outlook is mixed: analyst consensus is bullish with a $13.11 target, but near-term risks include pricing pressure in the egg market and earnings volatility. Recovery hinges on stabilizing supply costs and executing strategic options. Investors should weigh low valuation against operational challenges and industry headwinds for potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
